4 completed, 4 recruiting, 3 active not recruiting, 1 terminated. 9 Phase 2, 5 Phase 1, 1 Phase 3, 1 Phase 4.
Follow Advanced Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Advanced Head and Neck Squamous Cell Carcinoma trials Research Report on Advanced Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 28 | 2025-11-18 | 2026-06-26 |
| Influencing Factors for Physical Activity in People With Head and Neck Cancer Advanced Head and Neck Squamous Cell Carcinoma | Completed | Kantonsspital Winterthur KSW | 20 | 2024-03-30 | 2025-08-29 | |
| A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers HMBD-001, Docetaxel, Cetuximab - Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Hummingbird Bioscience | 398 | 2024-02-05 | 2026-05-27 |
| PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma Pembrolizumab, MET-4, Placebo - Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Canadian Cancer Trials Group | 2023-05-12 | 2023-05-18 | |
| A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®] - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer | Phase 1 / Phase 2 | Completed | Cytovation AS | 6 | 2023-03-21 | 2025-11-28 |
| Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer Cisplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 475 | 2022-02-01 | 2026-10-23 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Duvelisib, Docetaxel - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Kartik Sehgal, MD | 26 | 2021-10-14 | 2026-09-29 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy - Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Wake Forest University Health Sciences | 21 | 2021-02-25 | 2025-11-19 |
| A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma CDX-3379 and cetuximab - Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Celldex Therapeutics | 30 | 2018-03-27 | 2023-04-03 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab - Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 51 | 2016-12-22 | 2026-08-10 |
Squamous Cell Carcinoma of Head and Neck (7) · Carcinoma, Non-Small-Cell Lung (3) · Oropharyngeal Neoplasms (3) · Carcinoma (2) · Laryngeal Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Mouth Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Chondrosarcoma (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Head and Neck Neoplasms (8) · Carcinoma (7) · Carcinoma, Squamous Cell (6) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Pharyngeal Diseases (3)
pembrolizumab (4) · Cetuximab (2) · Docetaxel (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Biopsy (1) · CIMAvax EGF (1) · Cisplatin (1) · Disulfides (1) · Immune Checkpoint Inhibitors (1) · Immunoglobulin G (1) · Immunotherapy (1) · Nivolumab (1)
Canadian Cancer Trials Group (1) · Celldex Therapeutics (1) · Cytovation AS (1) · Hummingbird Bioscience (1) · Kantonsspital Winterthur KSW (1) · Kartik Sehgal, MD (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · University of Michigan Rogel Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (10) · Switzerland (2) · Australia (1) · Canada (1) · France (1) · Hong Kong (1) · Ireland (1) · Italy (1) · Moldova (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)
Anna Spreafico (1) · Kartik Sehgal, MD (1) · Martina Schmocker, MSc (1) · Maura L Gillison (1) · Mercedes Porosnicu, MD (1) · Paul L Swiecicki (1) · Paul M Harari (1) · Prantesh Jain, MD (1) · Rajat Thawani (1) · Timothy A Yap, MD (1)
PMID 31308059, PMID 37199326, PMID 42313403
U10CA180868 (2), P30CA012197 (1)